GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

bioAffinity Technologies BIAF · USD

Health Care · US listing · 🇺🇸 United States

Compare

2.26

-16.91%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About bioAffinity Technologies

From its filings with the US Securities and Exchange Commission

SEC filings

bioAffinity Technologies is based in San Antonio, Texas and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BIAF. The SEC classifies its business as commercial physical & biological research. In the fiscal year to 31 December 2025, it reported revenue of $6.2m and a net loss of $14.9m. At that date it held total assets of $11.0m and shareholders' equity of $7.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
26 Aug 2022
Employees
14
Head office
3300 NACOGDOCHES ROAD, SAN ANTONIO, TX, 78217
Incorporated in
DE
Classification
Services-Commercial Physical & Biological Research
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Steven GirgentiExecutive Chairman of the Board, since 2014$306,679
  • Ms. Maria ZannesPresident, Chief Executive Officer, Director, since 2014$477,155
  • Mr. James EdwardsChief Financial Officer, since 2024$273,213
  • Mr. Xavier RevelesChief Operating Officer
  • Mr. Timothy ZannesExecutive Vice President, General Counsel, Secretary
  • Dr. William BautaChief Science Officer
  • Mr. Gordon DownieChief Medical Officer
  • Dr. Roby JoyceDirector$611,905
  • Dr. John OppenheimerDirector
  • Mr. Roberto RiosDirector
  • Mr. Robert AndersonIndependent Director$137,498
  • Mr. Peter KnightIndependent Director$139,998

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • bioAffinity Technologies Inc employs 14 full-time employees in San Antonio, Texas.
  • CyPath Lung is the lead product for noninvasive early-stage lung cancer detection.
  • OncoSelect Therapeutics LLC advances cancer therapeutics targeting cancer cells selectively.

Weaknesses

  • The company has only 14 employees as a development-stage firm.
  • bioAffinity Technologies went public on 26 August 2022.
  • The company focuses solely on cancer diagnostics and therapeutics.

Opportunities

  • Expanding platform technologies for various cancer types and diseases.
  • Developing noninvasive diagnostic tests for lung diseases beyond cancer.
  • Advancing therapeutics through OncoSelect Therapeutics LLC.

Threats

  • Limited employee count may hinder rapid development and market expansion.
  • The biotechnology sector faces intense competition for cancer treatments.
  • Regulatory challenges in bringing new cancer diagnostics to market.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.